Objective To analyze the clinical application value of circulating tumor cells(CTCs)in the diagnosis and treatment of lung tumor patients.Methods A total of 14 patients with benign lung tumors and 40 patients with malignant lung tumors admitted to the thoracic surgery department of our hospi-tal from April 2020 to April 2022 were selected.The CTCs levels of patients before and one month after surgery were detected using ligand targeted polymerase chain reaction(PCR).The relationship between pe-ripheral blood CTCs levels and clinical data was analyzed,and the patients were followed up.Data were analyzed using chi-square test,Wilcoxon rank sum test,and Cox regression.Results The positive rate of CTCs in patients with malignant lung tumors was significantly higher than that in patients with benign lung tumors[75.0％(30/40)vs.35.7％(5/14),x2=7.018,P＜0.05].The positive expression rate of CTCs was not significantly correlated with gender,age and histological type(x2=0.320,2.133,0.076,P＞0.05),but with tumor pathological stage(x2=3.372,P＜0.001)and maximum diameter(x2=3.843,P＜0.001).Positive CTC was a risk factor for postoperative metastasis and recurrence in lung cancer patients[hazard ratio(HR):0.145,95％confidence interval(CI):0.031-0.685,P＜0.05].Conclusion The level of CTCs in lung cancer patients is correlated with tumor TNM staging,which is beneficial for determining the nature of lung nodules,aiding in the diagnosis of lung tumors,prognosis e-valuation,and postoperative guidance for treatment.
NETL
NSTL
万方数据
